2015 — Began a new Ebola vaccine study in Abuja, Nigeria, using a monovalent chimpanzee adenovirus Type 3 (ChAd3) candidate developed at the NIAID and being developed by GlaxoSmithKline (GSK), the study sponsor. (hivresearch.org)
«It's not just the indirect effect of protecting the mom, so it's therefore protecting the baby,» says Klein, of the Kaiser Permanente Vaccine Study Center in Oakland, Calif. «This is actually directly giving an immune response to the baby when you vaccinate during pregnancy.» (sciencenews.org)
The new formula's reduced effectiveness is most likely driving the recent epidemics of pertussis, says the study's lead author, Nicola Klein, co-director of Kaiser Permanente Vaccine Study Center in Oakland, Calif.. (scientificamerican.com)